Showing 1291-1300 of 1635 results for "".
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati
- Study Identifies "Visual System" Protein for Circadian Rhythm Stabilityhttps://modernod.com/news/study-identifies-visual-system-protein-for-circadian-rhythm-stability/2482033/Scientists at the Johns Hopkins University School of Medicine and the National Institutes of Health have identified a protein in the visual syste
- ECM Therapeutics Collaborates with the University of Pittsburgh Vision Institute to Advance Technology for Optic Nerve Repairhttps://modernod.com/news/ecm-therapeutics-collaborates-with-the-university-of-pittsburgh-vision-institute-to-advance-technology-for-optic-nerve-repair/2482023/ECM Therapeutics announced a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute to leverage a platform technology called Matrix Bound Nanovesicles (MBV) that has recently shown potential to promote restoration of injure
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- UAlbany Scientists Explore New Molecular Tool to Treat Retinal Degenerative Diseasehttps://modernod.com/news/ualbany-scientists-explore-new-molecular-tool-to-treat-retinal-degenerative-disease/2482011/University at Albany scientists at the College of Arts and Sciences’ RNA Institute, in collaboration with a research team from the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences, have received a 4-year, $1.8 million grant from the National Eye
- Ophtec Launches Precizon Go IOL for Enhanced Intermediate Visionhttps://modernod.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/Ophtec announced the launch of the Precizon Go, a hybrid acrylic IOL designed to provide distance and enhanced intermediate vision. The lens is designed to offer natural vision at far and enhanced intermediate vision, without compromising the quality of vision at any
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh
- NEI Director Highlights Metabolomics as an Approach to Understanding Glaucomahttps://modernod.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/The National Eye Institute (NEI) announced that NEI Director Michael F. Chiang, MD, featured recent research by NEI grantee Louis Pasquale, MD, in a National Institute of Health Director’s Blog post. Dr. Pasquale in collaboration with Jae Hee Kang, ScD, and Oana Zeleznik, PhD, explored 369
- Pixium Vision Receives Takeover Offerhttps://modernod.com/news/pixium-vision-receives-takeover-offer/2481976/Pixium Vision, whose safeguard proceedings were converted into receivership by the Paris Commercial Court on November 13, 2023, announced that the court-appointed administrators have received a takeover offer for the assets and activities of Pixium. The name of the a
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t